Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom

View original at nasdaq.com
“TSMC anticipates its operating profit margin to be 57.5% in Q2 (at the midpoint of its guidance range).”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia anticipates $1 trillion in AI data center chip sales in 2026 and 2027

    60% confidence
  • TSMC expects revenue to increase by more than 30% in 2026, revised from earlier forecast of close to 30%

    60% confidence
  • Broadcom sees $100 billion in AI chip revenue in fiscal 2027, up from $20 billion in fiscal 2025

    60% confidence
  • TSMC is expected to continue raising prices for its advanced chip nodes over the next four years

    60% confidence
  • TSMC anticipates operating profit margin of 57.5% in Q2 2026 at the midpoint of guidance range

    60% confidence
  • TSMC could be the ultimate pick-and-shovel AI stock for 2026 and beyond due to its wider reach in AI chips than Nvidia and Broadcom

    60% confidence
  • Stock Advisor's total average return is 994%, outperforming the S&P 500's 199%

    60% confidence
  • TSMC forecasts 32% year-over-year revenue increase in Q2 2026 to $39.6 billion

    60% confidence

Data points we hold from this source

Taiwan Semiconductor Manufacturing Company · forward earnings multiple25 ratio
Taiwan Semiconductor Manufacturing Company · net profit margin50.5 percent
Taiwan Semiconductor Manufacturing Company · eps3.49 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom — Source | Via News | ViaNews EU